Andrew Wood, MD, MS | Urology | Michigan Medicine

Biography

Andrew M. Wood, M.D. is a urological surgeon specializing in the surgical treatment and management of urologic cancers, including prostate, bladder, and kidney cancers. With advanced fellowship training in complex open, minimally invasive laparoscopic/robotic, and focal ablative techniques for Urologic cancers, he is able to apply the correct tool according to each patient’s unique clinical situation.

Dr. Wood’s research interests focus on the investigation and optimization of imaging-guided ablative therapies for prostate and kidney cancer. By enhancing the understanding of the interplay between advanced imaging technologies such as Prostate MRI and ablative modalities such as high-intensity focused ultrasound, cryotherapy, and irreversible electroporation, he hopes to continuously improve the oncologic and patient centered outcomes of these important cutting-edge techniques.

Dr. Wood was born and raised in Michigan and graduated from the University of Michigan before receiving his MD from Georgetown University School of Medicine. He completed his urology residency in New York City at Maimonides Medical Center. Subsequently, he completed a Society of Urologic Oncology (SUO) fellowship at the Cleveland Clinic before returning home to join the faculty at the University of Michigan.

Appointments

Urologic Oncology

Areas of Interest

Clinical Interests:

Prostate Cancer: Focal therapy for intermediate risk prostate cancer, Transperineal prostate biopsy and MRI fusion techniques, robotic prostatectomy, nerve-sparing surgical techniques

Bladder Cancer: Non muscle invasive disease risk stratification, minimally invasive radical cystectomy and urinary diversion surgery

Kidney Cancer: Open and minimally invasive surgical approaches (i.e., laparoscopic and robotic) for small and large masses with vascular involvement

Testis Cancer: Open and minimally invasive retroperitoneal lymph node dissection for large post-chemotherapy residual masses

Research Interests:

Improvement of clinical risk stratification and clinical decision making in patients with localized prostate cancer, bladder cancer, and kidney cancer. Of particular interest is the ways in which advanced imaging evaluation including artificial intelligence can be used to choose appropriate therapies, including focal/minimally invasive therapies, in patients with prostate cancer and kidney cancer.